Cut-to-Fuse Strategy Enables Molecular Skeletal Editing

Restructuring existing molecules without starting from scratch has become a high‑priority objective in contemporary organic chemistry, as researchers seek more efficient routes to complex compounds. The emerging strategy of skeletal editing—modifying the carbon framework of a target molecule—offers a way to generate new chemical architectures while preserving much of the original synthetic effort. By altering bond connectivity directly on a pre‑built scaffold, chemists can bypass lengthy multistep syntheses that traditionally required de novo construction.

Recent studies demonstrate that skeletal editing can streamline the creation of drug‑like molecules, enabling rapid exploration of structural analogues that might improve potency or pharmacokinetic properties. Techniques such as radical-mediated bond cleavage, transition‑metal catalysis, and photochemical rearrangements have been applied to transform readily available intermediates into novel frameworks. These methods allow for the late‑stage diversification of lead compounds, reducing the time and cost associated with medicinal‑chemistry campaigns.

The ability to edit a molecule’s skeleton on demand holds promise for accelerating pharmaceutical development. By simplifying synthesis pathways and expanding the chemical space accessible to drug designers, skeletal editing could shorten the timeline from discovery to clinical candidate. As the field matures, its integration into industrial workflows may become a standard tool for generating next‑generation therapeutics.